J. Craig Venter's Human Longevity, Inc. has added another piece to the data tapestry it is creating. The new addition is a registry of 11,000 twins, complete with phenotypic information and paired samples.
J. Craig Venter has made new hires at two of his companies.
While there is a well-established path from seed funding to exit for web startups, genomics plays with big ambitions require investors with deep pockets and an appetite for risk. Bryan Johnson seemingly has both and has set up a $100 million fund with the objective of turning "crazy" ideas into "viable" businesses.
Venter has gone to Mountain View to make his latest hire, nabbing Franz Och to build a Google Translate for genomics.
NIH has signed on to give the J. Craig Venter Institute $25 million over 5 years to study infectious diseases including influenza and malaria, working to spotlight new treatments.
Having outlined the ambitious plans for his latest venture in March, J. Craig Venter has begun to flesh out the team and capabilities Human Longevity will need to fulfill his vision.
In the months since details of Google's Calico last leaked into the public domain, the creation of a new J. Craig Venter company has further increased interest in anti-aging. And while Calico has been out of the headlines, it has continued to build out its anti-aging dream team, with a UCSF geneticist the latest to join.
The use of genomics to understand aging has become a high-profile field in recent months, with J. Craig Venter's Human Longevity and Google's Calico both researching the topic. Now Scripps has given the rest of the sector a new resource--whole genome sequences of 454 healthy elderly people.
The company J. Craig Venter founded in 1998 to challenge the Human Genome Project ran a data center with 70 terabytes of storage. Venter's latest scheme--creating the world's largest sequencing center--will fill that in less than one week.
J. Craig Venter, the aggressively confident gene sequencing and synthetic biology pioneer, is co-founding a new diagnostic and therapeutic startup focused on aging-related diseases. The company, dubbed Human Longevity Inc., rolls out of the starting gate with $70 million in initial investor funding.